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AbstrAct
Introduction Exercise-based cardiac rehabilitation (CR) 
independently alters the clinical course of cardiovascular 
diseases resulting in a significant reduction in all-cause 
and cardiac mortality. However, only 15%–30% of all 
eligible patients participate in a phase 2 ambulatory 
programme. The uptake rate of community-based 
programmes following phase 2 CR and adherence to 
long-term exercise is extremely poor. Newer care models, 
involving telerehabilitation programmes that are delivered 
remotely, show considerable promise for increasing 
adherence. In this view, the PATHway (Physical Activity 
Towards Health) platform was developed and now needs to 
be evaluated in terms of its feasibility and clinical efficacy.
Methods and analysis In a multicentre randomised 
controlled pilot trial, 120 participants (m/f, age 40–
80 years) completing a phase 2 ambulatory CR programme 
will be randomised on a 1:1 basis to PATHway or usual 
care. PATHway involves a comprehensive, internet-
enabled, sensor-based home CR platform and provides 
individualised heart rate monitored exercise programmes 
(exerclasses and exergames) as the basis on which to 
provide a personalised lifestyle intervention programme. 
The control group will receive usual care. Study outcomes 
will be assessed at baseline, 3 months and 6 months after 
completion of phase 2 of the CR programme. The primary 
outcome is the change in active energy expenditure. 
Secondary outcomes include cardiopulmonary 
endurance capacity, muscle strength, body composition, 
cardiovascular risk factors, peripheral endothelial vascular 
function, patient satisfaction, health-related quality of 
life (HRQoL), well-being, mediators of behaviour change 
and safety. HRQoL and healthcare costs will be taken into 
account in cost-effectiveness evaluation.
Ethics and dissemination The study will be conducted in 
accordance with the Declaration of Helsinki. This protocol 
has been approved by the director and clinical director 
of the PATHway study and by the ethical committee of 
each participating site. Results will be disseminated via 
peer-reviewed scientific journals and presentations at 
congresses and events.
Trial registration number NCT02717806. This trial is 
currently in the pre-results stage.
IntroductIon
Cardiovascular diseases (CVD) are the major 
reason for premature death and disability 
in Europe, resulting in approximately 
4.3 million deaths and costing the European 
Union €196 billion per year.1–3 Studies over 
the last decades have shown an increasing 
prevalence and incidence of CVD. Incidence 
increased by 5% from 1990 to 2000 and an 
additional increase of 25% is expected by 
2030.1 3 With these expected increasing 
numbers of patients eligible for cardiac reha-
bilitation (CR), the importance of CR will 
only grow.
Exercise-based CR favourably and inde-
pendently alters the clinical course of CVD 
with a 15%–31% reduction in all-cause and 
cardiac mortality.4 5 Peak aerobic capacity 
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Protocol
Strengths and limitations of this study
 ► PATHway (Physical Activity Towards Health) provides 
comprehensive cardiac rehabilitation in the living 
room of the patient.
 ► The telerehabilitation intervention is fully 
personalised on the patients' needs, goals and 
preferences.
 ► This pilot study could justify prospective trials to 
evaluate the longer-term effects of the PATHway 
platform on cardiovascular health.
 ► The study is of relatively short duration and no data 
will be available after 6 months.
 ► The study is underpowered to detect statistically 
significant changes for a majority of secondary 
outcomes.
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appears to be a strong predictor of mortality in patients 
with CVD.6–8 Hence, the impetus to improve exercise 
capacity in patients with CVD in the short term and main-
tain this improvement in the longer-term is strong. There 
is overwhelming evidence coming from meta-analytic 
research showing that exercise-based CR programmes 
are able to significantly increase this exercise capacity by 
20%–30%.9 Based on such accumulating evidence, phys-
ical activity counselling and exercise training are now 
core components in all secondary prevention guidelines 
for patients with cardiac disease.1 10
However, only 15%–30% of all patients eligible for 
CR engage in a formal exercise programme (phase 
2 ambulatory programme).11 Moreover, uptake rates 
of community-based CR following these phase 2 
programmes are even lower and the number of patients 
effectively continuing the long-term rehabilitation 
phase is extremely poor.11 Optimising CR delivery and 
improving the ongoing adoption of a healthy lifestyle 
will be important for the health and well-being of the 
general population and from the perspective of health-
care costs. The main reasons for the low adherence rates 
include: travel distance, low self-efficacy, perceived body-
image and lack of time.12 Therefore, it is a priority to find 
effective interventions that result in a lifelong physically 
active lifestyle. Ideally, such interventions should lead 
to a sustainable cardioprotective lifestyle resulting in an 
increase of moderate to vigorous physical activity and 
an improved physical fitness, enhancing both survival 
and health-related quality of life (HRQoL) at a cost that 
represents good value for money for health systems.
An evidence-based approach to inducing sustained 
lifestyle changes involves the implementation of health 
behaviour change strategies grounded in health behaviour 
change theory.13 A range of health behaviour change 
techniques can be used to enhance intervention effective-
ness.14 Frequent feedback and the provision of motivation 
and support have been shown to be efficacious.15 16 Setting 
realistic goals and individualising the programme to the 
needs and interests of the patient improves compliance 
to physical activity and exercise.17 To this end, state-of-
the-art telerehabilitation18 technology has the potential to 
help participants by inducing sustained lifestyle changes 
and health providers by providing personalised health 
services.19 Patients with CVD show high interest in tech-
nology enabled CR, providing a clear indication to 
develop such interventions.20
PATHway (Physical Activity Towards Health) is a novel 
approach set within a collaborative care context with 
health professionals that aims to empower participants to 
self-manage their CVD risk factors. This will be achieved 
using a patient-centric holistic behavioural change 
approach that involves an internet-enabled and sensor-
based home exercise platform as the core component 
of a personalised, comprehensive lifestyle intervention 
programme. This will enable participants to both better 
understand and deal with their own condition and adopt 
and/or maintain a healthy lifestyle in general.
AIms And objectIves
The study will use a single blind multicentre pilot 
randomised controlled clinical trial to assess the impact 
of the PATHway platform on physical activity, lifestyle and 
health-related physical fitness in patients with CVD and to 
evaluate the acceptability, feasibility and cost-effectiveness 
of using PATHway in patients with CVD.
Primary objective of the trial
The primary objective is to compare objectively measured 
active energy expenditure. We hypothesise that physical 
activity defined as the total weekly volume of active (activ-
ities requiring an energy expenditure >3 metabolic units) 
energy expenditure (EE in kcal) will be significantly 
greater in the intervention (PATHway) than the control 
group (usual care) at 6 months.
secondary objectives of the trial
 ► Compare cardiopulmonary endurance capacity, 
muscle strength and muscle endurance, flexibility, 
cardiovascular risk score and body composition.
 ► Compare psychosocial well-being and quality of 
life including depression, self-efficacy and social 
relationship.
 ► Participants are much more likely to adhere to 
PATHway if they understand the system and like how 
it operates. Through process evaluation the feasibility, 
acceptability, satisfaction and usability of the PATHway 
system from the participants’ perspective will be 
assessed.
 ► Explore the determinants/moderators of health 
behaviour change and CV health.
 ► Estimate the cost-effectiveness of PATHway.
 ► Assess the safety of PATHway.
 ► Evaluate whether the decision support system (DSS) 
of PATHway ensures the safety of the participants, 
optimises the exercise programme according to 
patient needs and contributes to health behaviour 
change.
methods
The PATHway study protocol is reported following the 
Standard Protocol Items: recommendations for Interven-
tional Trials (SPIRIT) 2013,21 22 the checklist of which can 
be found as the added Research Checklist. This trial is 
registered at  ClinicalTrials. gov: NCT02717806.
study design
A single blind, parallel two-group pilot multicentre 
randomised controlled design will be employed. A total 
of 120 participants will be randomised to the PATHway 
intervention or usual care. Given the nature of the inter-
vention, it is not possible to blind the participants or 
the researchers implementing PATHway. Researchers 
performing the outcome assessments will, however, be 
blinded to patient allocation. Figure 1 shows the study 
flow.
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Figure 1 Study schedule. CR, cardiac rehabilitation; PATHway, Physical Activity Towards Health.
study setting
Participants will be recruited among patients with cardiac 
disease participating in three outpatient CR programmes in 
Belgium and Ireland. Sixty participants will be recruited in 
the University Hospitals Leuven (Belgium), 30 participants 
will be recruited from the community clinic at Beaumont 
Hospital, Dublin (Ireland) and another 30 participants 
will be recruited from the community clinic at The Mater 
Misericordiae University Hospital, (Ireland). The Univer-
sity of Leuven will be the coordinating centre for the trial. 
Daily management of the study will be performed by a 
local principal investigator at each participating site.
eligibility criteria and recruitment
The study population will comprise 120 patients diag-
nosed with CVD. Men and women between the ages of 
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Table 1 Inclusion and exclusion criteria for the PATHway (Physical Activity Towards Health) trial
Inclusion criteria Exclusion criteria
 ►Men and women with documented cardiovascular disease 
who are enrolled for the first time in a CR programme
 ►Aged 40–80 years
 ►Participants are on optimal medical treatment and stable 
with regard to symptoms and pharmacotherapy for at least 
4 weeks
 ►Participants must complete the ambulatory CR programme 
and receive clinical approval from their treating physician to 
continue exercising outside the hospital programme
 ► Internet access at home
 ►Sufficient space to deploy and use the system adequately
 ►Significant illness during the last 6 weeks
 ►Known severe ventricular arrhythmia with functional or 
prognostic significance
 ►Significant myocardial ischaemia, haemodynamic 
deterioration or exercise-induced arrhythmia at baseline 
testing
 ►Cardiac disease that limits exercise tolerance (valve disease 
with significant haemodynamic consequences, hypertrophic 
cardiomyopathy and so on)
 ►Comorbidity that may significantly influence 1-year 
prognosis
 ►Functional or mental disability that may limit exercise
 ►Acute or chronic inflammatory diseases or malignancy, the 
use of anti-inflammatory drugs or immune suppression
 ►Severe chronic obstructive pulmonary disease (FEV1<50%)
 ►NYHA class 4
 ►Participation in another clinical trial
CR, cardiac rehabilitation. 
40–80 years with documented CVD, who enrol for the first 
time in an outpatient CR programme, will be recruited 
during a 1-year period starting in May 2017. Participants 
entering the CR programme will be assessed for eligi-
bility by the local hospital cardiac nurse (Ireland) or 
physiotherapist (Belgium). A detailed description of the 
inclusion and exclusion criteria is shown in table 1. Identi-
fied eligible participants will be contacted by a member of 
the research team at DCU and KU Leuven and provided 
with a full oral explanation of the design and purpose of 
the study, responsibilities of the participants, reasonable 
foreseeable inconveniences, confidentiality of the infor-
mation collected. Patients who agree to participate will 
provide contact details and basic sociodemographic data.
randomisation and concealed allocation
After signing an informed consent, participants will be 
randomised to either the PATHway-intervention or the 
usual care group. Randomisation will be performed in 
a 1:1 ratio, stratified by centre of enrolment. Randomi-
sation schedules will be generated for each centre using 
a computerised random number generator. In order to 
assure concealment of allocation and minimise selection 
bias, an independent designated member of the coordi-
nating centre in KU Leuven will assign a randomisation 
number in response to a request from a local investigator. 
Participants will receive a personalised identification 
code (PIC) which will be used on all subsequent tran-
scripts and data collected to assure anonymity of all data.
sample size calculation
As this is the first study with this type of complex interven-
tion, without precedence on which to base accurate power 
calculations, a power calculation has not been performed. 
A major aim of the study is to provide evidence showing an 
increased uptake/compliance to a short-term technolo-
gy-based physically active lifestyle intervention compared 
with usual care. It is envisaged that the study findings will 
provide data for the design of a larger randomised trial 
examining a technology-based physically active lifestyle 
intervention compared with usual care. We have chosen 
a convenience sample of 120 participants, in order to 
assess the plausible effects of short-term technology-based 
physically active lifestyle intervention on physical activity 
uptake as well as to provide an indication of the effect size 
on health-related fitness which we envisage would be the 
primary outcome of a future larger trial in patients with 
CVD.
PAthway intervention
As shown in figure 1, eligible and consenting participants 
will be enrolled prior to discharge from an outpatient 
ambulatory CR programme. In addition to the 2–3 weekly 
exercise sessions as part of the outpatient CR programme, 
participants allocated to the PATHway intervention will 
also undertake a single supervised familiarisation session 
during each of the last 4 weeks in order to systematically 
learn and practice all features of the platform. During this 
familiarisation period, a local investigator will install the 
PATHway system in the participant’s home. Participants 
will be provided with a standardised training manual 
and set-up guide. During the familiarisation period, they 
will be requested to interact with the PATHway system 
by means of standardised assignments to assure they get 
acquainted with its features. Subsequently, participants 
will be encouraged to discuss their experience with the 
PATHway technology and identify problems.
The home-based PATHway system will provide an indi-
vidualised exercise prescription based on the results of 
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Figure 2 An overview of the PATHway (Physical Activity Towards Health) components: 1, the patient experiences a cardiac 
event; 2, the patient is treated in the hospital; 3, the patient participates in a phase 2 cardiac rehabilitation (CR) programme; 
4+5+6, the patient uses PATHway after completion of phase 2 CR; 7, the patient is able to socially interact with other PATHway 
users via the system; 8, patient data are transmitted and used as feedback for the patient and health professionals; 9, this can 
allow an improvement of care by the health professional; 10+12, the patient can also monitor outdoor activities and upload 
them to the system afterwards; 11, patient data are aggregated and allow for possibility of undertaking large-scale, accurate, 
longitudinal health-based research—‘crowd sourced researching’ (13).
a cardiopulmonary exercise test performed at the start 
of the familiarisation period and according to current 
guidelines.1 23–30 Additionally, a behavioural change 
component that allows realistic goal setting by the patient 
will be implemented with regard to diet, smoking cessa-
tion, alcohol, stress reduction and medication adherence. 
Guiding the patient to choose appropriate goals that focus 
on specific achievable health behaviour changes has been 
shown previously to promote goal attainment.13 Patients 
will be asked to complete the behaviour change assess-
ment module during this familiarisation phase. Following 
this assessment, patients will be asked to choose a lifestyle 
behaviour they want to improve.
As shown in figure 2, the PATHway intervention is 
a comprehensive and complex self-care CR system. It 
involves the implementation of an end-to-end modular 
technology platform (ie, portable PC including PATHway 
software, Microsoft Kinect camera, Microsoft Band 2 
heart rate monitor, Blood pressure device, Zensor 3-lead 
ECG device) that allows participants to better self-manage 
their illness. PATHway consists of five different modules; 
exercise, outdoor physical activity, behavioural change, 
social connectivity and affective response.
The home-based exercise module comprises an exer-
cise class (exerclass) and an exercise game (exergame) 
component. The exerclass includes dynamic aerobic 
exercises, dynamic resistance exercises and relax-
ation. Participant movements, repetition count, energy 
expenditure and heart rate (HR) will be continuously 
monitored by the Microsoft Band 231 in order to provide 
personalised feedback via a virtual ‘avatar’ coach and to 
continuously adapt the programme. A motion-capturing 
component using the Microsoft Kinect sensor will assess 
participants’ movements during the exerclass and exer-
game sessions and provide them with feedback on the 
accuracy of their exercise execution. A DSS using HR 
(Microsoft Band 2)31 along with the accuracy derived 
from the motion capturing component will be used to 
dynamically select exercises during real time.32 In this 
context, the goal is to adjust32 the exercise prescription 
to achieve the prescribed target HR zone33 required to 
maintain and/or improve cardiovascular fitness. Finally, 
a prescreening data processing component will evaluate 
the participants resting HR and blood pressure, medica-
tion compliance and eating behaviour prior to starting 
each exercise session.
The exercise module will be supplemented by an outdoor 
physical activity module. A wrist worn HR/physical activity 
monitor (Microsoft band 2) will assess sitting behaviour 
and physical activity levels beyond the exerclasses and 
exergames. The combined data derived from the exercise 
module and outdoor physical activity assessment module will 
be aggregated to generate a physical activity report. The 
report will allow participants to monitor their physical 
activity behaviour and will provide the healthcare profes-
sionals with objective data relating to physical activity, 
sedentary behaviour and compliance.
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Substantial evidence indicates that telerehabilitation 
interventions are more effective when they incorpo-
rate a behaviour change module such as self-monitoring, 
providing feedback on performance, goal-setting and 
rewards.34 Behaviour change techniques based on the 
taxonomy developed by Michie and colleagues14 will 
be implemented in the PATHway platform within a 
behavioural change module. These will be delivered implic-
itly and according to patient preferences throughout 
the system as well as via the avatar, text-based resource 
content and push notifications linked with performance 
feedback.35
To further facilitate social support within a commu-
nity context, a social connectivity module will enable small 
groups of remote participants to exercise together by 
allowing them to communicate during the exercise 
session by means of headsets, as well as by sending 
messages and a live chat function.36 An online calendar 
will also allow participants to promote events and to 
invite others to join, with a maximum of four partici-
pants per event.
The affective response module will use a questionnaire 
to measure the extent to which the participants enjoy 
each exercise session. The perceptions of effort, strain, 
discomfort or fatigue experienced during exercise will 
be measured using the Borg 16 point rating of perceived 
exertion (RPE) scale. The effect and RPE scores will be 
used to allow the PATHway platform to automatically 
adjust the exercise sessions offline according to the partic-
ipant’s levels of enjoyment and exertion.
An incorporated e-learning platform involving text, photo 
and video messaging information will provide partici-
pants with information on reducing lifestyle-related risk 
factors for CVD. A detailed overview of the PATHway 
system can be found elsewhere.37
Patients randomised to the PATHway intervention will 
be asked to use the system for 6 months following their 
outpatient CR programme.
usual care or control group
During the 4-week familiarisation period, participants 
allocated to the usual care group will continue to attend 
the hospital-based outpatient CR programme 3 days per 
week. At completion of the outpatient CR programme, 
they will receive advice on how best to maintain a phys-
ically active lifestyle. They will be free to participate in 
any type of fitness classes, walking groups, cycling groups, 
available community-based CR programmes and so on. 
However, they will not be provided with a specific exer-
cise prescription or receive direct feedback or support 
with regard to their physical activity behaviour during the 
6-month follow-up period.
concomitant care
Both intervention and control group will continue to 
receive medical and pharmacological management as 
well as the standard lifestyle advice according to prevailing 
guidelines.38 39
outcome measures and data collection
Outcome measures will be assessed by researchers blinded 
to the group allocation. All assessments will be performed 
at baseline (t1), which coincides with the start of the famil-
iarisation phase and at 3 months (t2) and 6 months (t3) 
after completion of the phase 2 CR programme unless 
otherwise specified (figure 1). Table 2 gives a tabulated 
summary of the study schedule and measurements.
Primary outcome
The primary outcome, total volume of weekly active energy 
expenditure (>3 METs), will be objectively measured by 
means of a validated physical activity device, the Acti-
Graph GT9X Link (ActiGraph, Pensacola, Florida, USA). 
Measurements of physical activity and exercise capacity40 
will be performed in the week before the PATHway run-in 
period. Both measurements will be repeated during the 
last week of both the third month (=t2) and the sixth 
month (=t3) following completion of the phase 2 CR 
period.
secondary outcomes
Health-related outcomes
At each data collection time point, participants will 
attend for a single visit between 09:00 and 12:00 hours 
following a 12-hour fast. After measurements of anthro-
pometrics, vascular health and blood sampling have been 
performed, they will be given the time to consume a light 
breakfast. Following this, measurements on flexibility and 
muscle function will be performed. All measurements will 
be performed by the same blinded researchers on each 
participating site. In the following order:
 ► Body composition: weight, height, fat percentage, 
waist and hip circumferences.41
 ► Vascular function will be assessed by measuring the 
percentage change in brachial artery flow mediated 
dilation following 5 min of forearm occlusion.42 43 
Blood pressure will be measured at rest (office BP) in 
sitting position.
 ► A 12-hour fasting blood sample will be drawn to 
measure selected biomarkers: fasting glucose, insulin, 
total cholesterol, high-density lipoprotein cholesterol, 
low-density lipoprotein cholesterol, triglycerides and 
HbA1C.
 ► Functional flexibility will be assessed by means of the 
timed sit and stand test.44
 ► Muscle strength will be measured using maximal 
isometric handgrip strength45 46 and isometric and 
isokinetic quadriceps strength and endurance.47
Psychosocial well-being and intervention effectiveness
Participants will fill in a booklet of questionnaires which 
will be administered as an online survey on a portable 
PC or tablet during the assessment visits. Furthermore, 
patients randomised to the PATHway intervention will 
also fill in a few further questionnaires on the PATHway 
platform, since needed for the health behavioural change 
module. These instruments assess among others, health, 
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Table 2 Tabulated summary of study schedule
Enrolment
T0
Baseline
T1
FU3m
T2
FU6m
T3
  Eligibility screen X
  Informed consent X
  Allocation X
  PATHway intervention
  Usual care (control) intervention
Assessments
  Physical activity X X X
  Demographic characteristics X X
  Health-related physical fitness
   CPET X X X
   Muscle strength and flexibility X X X
   Quality of the vascular system X X X
   Blood sampling X X
   Body composition X X X
  Health-related QoL and psychosocial well-being
   PHQ-9 X X X
   EQ-5D-5L questionnaire X X x
   SF-36 questionnaire X X X
   Exercise self-efficacy scale X X X
   Medication adherence X X X
   Exercise barriers X X X
   Perceived stress scale X X X
   ENRICHD X X X
  Satisfaction/usability tests X
  Resource use data collection X X X
  Safety monitoring
   Three-day ECG Holter monitoring X X X
   Adverse event reporting
  Process evaluation (assessment of DSS)
   Validation of DSS outcomes captured in 
reports by clinical experts
X X X
Satisfaction/usability test will only be performed in the intervention group.
CPET, cardiopulmonary exercise test; DSS, decision support system;  ENRICHD, Enhancing Recovery In Coronary Heart Disease; EQ-5D-5L, 
EuroQol-Five Dimensions-Five Levels Questionnaire; PHQ-9, Patient Health Questionnaire 9; QoL, Quality of Life; SF-36, Short Form 36; T, 
timepoint.
self-efficacy, well-being and quality of life. They will also 
collect data on the mechanisms hypothesised to mediate 
PATHway usage and maintenance of physical activity 
behaviour. An overview of the questionnaires used to 
assess outcome measures and guide risk factor behaviour 
change is shown in table 3. For an overview of the ques-
tionnaires administered at t1, t2 and t3 only, see table 2.
Health economic evaluation
The health economic evaluation will evaluate health 
outcomes and resource use consequences of the PATHway 
intervention. The analysis will be conducted from a 
societal perspective to include resource costs falling on the 
health service and on the individual, together with poten-
tial productivity benefits associated with return to work 
where applicable. HRQoL outcomes will be estimated in 
terms of Quality Adjusted Life Years (QALYs). These data 
will be generated using completed EuroQol-Five Dimen-
sions-Five Levels Questionnaires.48 The cost of delivering 
the programme, the health service costs, the costs falling 
on the participants and the productivity effects in terms 
of participant’s employment will be calculated. Informa-
tion on participants' resource use will be obtained by a 
researcher by means of an interviewer-administered 
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Table 4 Overview of main categories for health economics 
assessment
Direct healthcare costs
  Concomitant medications
  Visits to healthcare 
professionals
  Outpatient visits
  ER visits
  Inpatient admissions
Direct costs to the patient/carer
  Travel costs
  Home adaptations
Productivity costs to patient/carer
  Time away from 
employment/main activity
Quality of Life
  Quality of life EuroQol-Five Dimensions-
Five Levels Questionnaire
questionnaire at t1, t2 and t3 as shown in table 4. The 
incremental cost-effectiveness ratio will be calculated as 
the cost per QALY gained by using the intervention.
Observed results will be extrapolated beyond the 
6-month intervention period in the clinical trial, in order 
to explore the potential lifetime cost-effectiveness of 
PATHway. Statistical and decision-modelling methods will 
be used to undertake the extrapolation, which will apply 
to costs as well as effects. The model will link changes in 
exercise capacity and cardiovascular risk profiles to recur-
rent cardiovascular events and CVD mortality in order to 
estimate the cost-per-QALY associated with the PATHway 
programme. The post-trial extrapolation for each arm 
uses estimates of long-term recurrence from the litera-
ture and the observed recurrence rates within the period 
of the trial, accounting for any differences in resource 
use, life expectancy and quality of life.
Safety monitoring
All serious adverse events (SAE) will be reported contin-
uously to a Data Safety and Monitoring Committee 
composed of four cardiologists. SAE are defined as 
all-cause mortality, hospitalisation for CVD or serious 
atrial or ventricular arrhythmia. Other adverse events will 
include training-related adverse events such as muscle, 
tendon or joint problems that will preclude exercise 
participation or other diseases that require an interrup-
tion of the exercise intervention. Participants will also 
wear a 3-lead ECG Zensor Device (Intelesens, Belfast, 
North Ireland) monitoring system for three consecutive 
days at the three time points of measurement. The partic-
ipants will be asked to wear the Zensor simultaneously 
with the ActiGraph device.
Qualitative outcomes
The PATHway system one-on-one interviews guided by the 
Health IT Usability Evaluation Model (Health–ITUEM),49 
will be used to evaluate both subjective (perceived ease of 
use and perceived usefulness) and objective (efficiency 
and effectiveness) measures as part of the PATHway 
debrief, with participants and stakeholders (ie, physio-
therapists, cardiologists, cardiac nurses). Face-to-face 
interviews will be conducted by a trained interviewer to the 
point of data saturation. Participants will be asked about 
their opinions on the PATHway programme, especially 
in relation to perceptions of improved self-management 
and confidence in DSSs; the influence of peer mentors; 
the programme language; the level of content remem-
bered as well as perceptions of intrusiveness, timing and 
content. All interviews will be semistructured in nature to 
allow the extrapolation of novel patient-led topics in rela-
tion to the intervention. All interviews will be audio-taped 
and transcribed verbatim and analysed using Braun and 
Clarke’s thematic analysis five-step framework.50 Audit 
trails will be used throughout this analysis to ensure trans-
parency throughout the development process from raw 
interview transcripts to themes to user feedback formula-
tions to the technology team.
Data management and analysis
Each randomised participant will be assigned a PIC. This 
unique identification number will be used on all case report 
forms, electronic databases and within the PATHway plat-
form. Data will be recorded in hardcopy at the time of the 
measurement and will subsequently be entered electroni-
cally in ‘RedCap’, an open source clinical trial software for 
electronic data capture and data management. The data-
base will be hosted and secured hardcopies will be stored in 
a secured filing cabinet at the participating sites. The data 
entry screens in RedCap will resemble the hard copy case 
report forms approved by the ethical committee. Checks 
will be automatically applied when entering the data in the 
database based on preset ranges. Missing data will also be 
automatically detected and data query reports will be sent 
to the local data manager. The type of activity that an indi-
vidual user may undertake is regulated by the privileges 
associated with his/her user identification code and pass-
words. After submission of the data, researchers responsible 
at the participating sites cannot make any changes. Appro-
priate changes can only be made by the principle data 
manager.
All data analyses and reporting will be performed 
according to best practice and reported in agree-
ment with Consolidated Standards of Reporting Trials 
guidelines and the Consolidated criteria for reporting 
qualitative research.51–53 Data analysis will be performed 
using SAS version 9.4. Baseline demographic characteris-
tics and parameters related to pathology will be reported 
descriptively and will in first instance be compared across 
countries and between treatment groups to assess whether 
further analyses need adjustment for any unbalanced 
variables. In addition, these basic demographic char-
acteristics will be compared between non-participating 
eligible participants and eligible participants enrolled 
in the trial to evaluate the potential of selection bias. All 
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primary and secondary outcome parameters as previously 
described will be analysed on an intention-to-treat prin-
ciple according to initial randomisation and using data 
collected at 6 months following completion of the phase 
2 CR programme. To account for missing data, we will 
impute the missing value with the last measured value. 
The Shapiro-Wilk test will be applied to assess normality. 
The mixed linear models will be used to assess differ-
ences between groups. All tests will be two-sided and a 
p value<0.05 will be considered statistically significant.
ethIcs And dIssemInAtIon
The study will be conducted in accordance with the prin-
ciples stated in the Declaration of Helsinki.54 Participants 
will only be enrolled in the study after signing written 
informed consent. None of the principal investigators in 
the PATHway study have any financial interest to declare. 
This protocol and the template informed consent have 
been reviewed and approved by the director and clinical 
director of the PATHway study and are approved by the 
ethical committee of the UZ Leuven/ KU Leuven and the 
Research Ethics Committee of both Irish hospital part-
ners (KU Leuven: S59023; Mater Misericordiae Hospital 
Dublin: 1/378/1846; Beaumont Hospital Dublin: 16/50), 
as well as Dublin City University (DCU: REC2016/123) 
with respect to scientific content and compliance with 
applicable research and human subjects regulations. In 
case of any amendments to the consent form during the 
study, the volunteers will be given a copy of the updated 
form and any written information. We will disseminate 
the PATHway study results via peer-reviewed scientific 
journals and presentations at local, national and interna-
tional congresses and events.
conclusIon
It has recently been suggested that a comprehensive telere-
habilitation programme for participants with cardiac 
disease should include telemonitoring, telecoaching, social 
networking and e-learning in order to achieve significant 
long-term effects on the participants' health condition.18 
To date, most of the telerehabilitation programmes have, 
however, only included one or two of these components. 
Furthermore, although exercise and physical activity are 
key in a CR programme, current guidelines clearly state 
that a CR programme should involve all of the core compo-
nents.10 To the best of our knowledge, PATHway is the first 
system that provides such a comprehensive cardiac telere-
habilitation programme which is fully patient-tailored 
based on personal needs and preferences. More specific, 
participants will be provided with a personalised exercise 
prescription which will be formulated based on the clinical 
status of the participants and also taking personal prefer-
ences and exercise goals into account. In addition to this 
and based on an evaluation of other lifestyle behaviours, 
participants will be encouraged to set personalised goals 
for adopting a healthy lifestyle. An e-learning environ-
ment including written information and videos focusing 
on the different core components of secondary prevention 
programmes will help participants to get a better under-
standing of their disease and its management. It should be 
noted that PATHway was not designed to replace current 
supervised phase 2 CR programmes, but it aims to offer an 
alternative for those patients who cannot complete a phase 
2 CR programme due to work or other commitments and 
it is intended to support a physically active and healthy life-
style beyond the phase 2 programme. The main goal of 
this pilot trial is to gain insight into the change in health 
status of the patient and the efficacy of the system. This will 
allow further dissemination of the PATHway platform in 
the future.
lImItAtIons
As the study is of relatively short duration, no data will 
be available beyond 6 months. Furthermore, the study is 
underpowered to detect statistically significant changes 
for a majority of secondary outcomes. However, it might 
be anticipated that when we are able to demonstrate an 
increased uptake of physical activity 6 months following 
completion of the ambulatory phase 2 CR programme 
by using PATHway, this will result in an enhancement of 
cardiovascular health in the longer term. Hence, this study 
would then provide justification for prospective trials to 
evaluate the longer-term effectiveness on cardiovascular 
health and the cost-effectiveness of the PATHway platform 
in this population and also other chronic disease popula-
tions.
expected outcomes and future contributions
At this stage, PATHway aims to support patients with cardiac 
disease in maintaining a physically active lifestyle and where 
possible to further increase their levels of physical activity. 
In addition, it will help participants to choose a healthy life-
style. If the results of PATHway are positive, the PATHway 
platform can be extended to other patient populations with 
chronic disease including patients with peripheral artery 
disease, chronic stroke, chronic obstructive lung disease 
and also in the primary prevention of CVD in persons with 
established cardiovascular risk factors for whom exercise 
and the adoption of a healthy lifestyle is a core component 
in their disease management.
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